Ahnak functions as a tumor suppressor via modulation of TGFβ/Smad signaling pathway

I. H. Lee; M. Sohn; H. J. Lim; S. Yoon; H. Oh; S. Shin; J. H. Shin; S. H. Oh; J. Kim; D. K. Lee; D. Y. Noh; D. S. Bae; J. K. Seong; Y. S. Bae

doi:10.1038/onc.2014.69

Ahnak functions as a tumor suppressor via modulation of TGFβ/Smad signaling pathway

I. H. Lee, M. Sohn, H. J. Lim, S. Yoon, H. Oh, S. Shin, J. H. Shin, S. H. Oh, J. Kim, D. K. Lee, D. Y. Noh, D. S. Bae, J. K. Seong, Y. S. Bae

Department of Life Science

Research output: Contribution to journal › Article › peer-review

98 Scopus citations

Abstract

We provide detailed mechanisms of Ahnak-mediated potentiation of transforming growth factor β (TGFβ) signaling, which leads to a negative regulation of cell growth. We show that Smad3 interacts with Ahnak through MH2 domain and that Ahnak stimulates Smad3 localization into nucleus leading to potentiating TGFβ-induced transcriptional activity of R-Smad. Moreover, overexpression of Ahnak resulted in growth retardation and cell cycle arrest through downregulation of c-Myc and cyclin D1/D2. We describe results from analyses of Ahnak-/-mouse model expressing middle T antigen in a mammary gland-specific manner (MMTV Tg/+ Ahnak-/-), which showed significantly progressed hyperplasia of mammary glands compared with MMTV Tg/+ Ahnak +/+. Finally, we screened multiple human breast cancer tissues and showed that the expression of Ahnak in cancer tissues is lower than that in control tissues by 50%. Taken together, these data indicate that Ahnak mediates a negative regulation of cell growth and acts as novel tumor suppressor through potentiation of TGFβ signaling.

Original language	English
Pages (from-to)	4675-4684
Number of pages	10
Journal	Oncogene
Volume	33
Issue number	38
DOIs	https://doi.org/10.1038/onc.2014.69
State	Published - 18 Sep 2014

Bibliographical note

Funding Information:
This work was supported by the National Research Foundation of Korea (NRF) grant (No. 2012R1A5A1048236), by the Drug Target Validation program (No. 2009-0093987), by the Bio & Medical Technology Development Program (No. 2012M3A9B4028785) and by Redoxomics grant (No. 2012M3A9C5048708) funded by Ministry of Science, ICT & Future Planning, and the Ewha Womans University Research Grant of 2013 (to I.H.L.).

Publisher Copyright:
© 2014 Macmillan Publishers Limited All rights reserved.

Access to Document

10.1038/onc.2014.69

Cite this

@article{fdc6583c44d148fb9e2a830ccce9270d,

title = "Ahnak functions as a tumor suppressor via modulation of TGFβ/Smad signaling pathway",

abstract = "We provide detailed mechanisms of Ahnak-mediated potentiation of transforming growth factor β (TGFβ) signaling, which leads to a negative regulation of cell growth. We show that Smad3 interacts with Ahnak through MH2 domain and that Ahnak stimulates Smad3 localization into nucleus leading to potentiating TGFβ-induced transcriptional activity of R-Smad. Moreover, overexpression of Ahnak resulted in growth retardation and cell cycle arrest through downregulation of c-Myc and cyclin D1/D2. We describe results from analyses of Ahnak-/-mouse model expressing middle T antigen in a mammary gland-specific manner (MMTV Tg/+ Ahnak-/-), which showed significantly progressed hyperplasia of mammary glands compared with MMTV Tg/+ Ahnak +/+. Finally, we screened multiple human breast cancer tissues and showed that the expression of Ahnak in cancer tissues is lower than that in control tissues by 50%. Taken together, these data indicate that Ahnak mediates a negative regulation of cell growth and acts as novel tumor suppressor through potentiation of TGFβ signaling.",

author = "Lee, {I. H.} and M. Sohn and Lim, {H. J.} and S. Yoon and H. Oh and S. Shin and Shin, {J. H.} and Oh, {S. H.} and J. Kim and Lee, {D. K.} and Noh, {D. Y.} and Bae, {D. S.} and Seong, {J. K.} and Bae, {Y. S.}",

note = "Funding Information: This work was supported by the National Research Foundation of Korea (NRF) grant (No. 2012R1A5A1048236), by the Drug Target Validation program (No. 2009-0093987), by the Bio & Medical Technology Development Program (No. 2012M3A9B4028785) and by Redoxomics grant (No. 2012M3A9C5048708) funded by Ministry of Science, ICT & Future Planning, and the Ewha Womans University Research Grant of 2013 (to I.H.L.). Publisher Copyright: {\textcopyright} 2014 Macmillan Publishers Limited All rights reserved.",

year = "2014",

month = sep,

day = "18",

doi = "10.1038/onc.2014.69",

language = "English",

volume = "33",

pages = "4675--4684",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Nature Publishing Group",

number = "38",

}

TY - JOUR

T1 - Ahnak functions as a tumor suppressor via modulation of TGFβ/Smad signaling pathway

AU - Lee, I. H.

AU - Sohn, M.

AU - Lim, H. J.

AU - Yoon, S.

AU - Oh, H.

AU - Shin, S.

AU - Shin, J. H.

AU - Oh, S. H.

AU - Kim, J.

AU - Lee, D. K.

AU - Noh, D. Y.

AU - Bae, D. S.

AU - Seong, J. K.

AU - Bae, Y. S.

N1 - Funding Information: This work was supported by the National Research Foundation of Korea (NRF) grant (No. 2012R1A5A1048236), by the Drug Target Validation program (No. 2009-0093987), by the Bio & Medical Technology Development Program (No. 2012M3A9B4028785) and by Redoxomics grant (No. 2012M3A9C5048708) funded by Ministry of Science, ICT & Future Planning, and the Ewha Womans University Research Grant of 2013 (to I.H.L.). Publisher Copyright: © 2014 Macmillan Publishers Limited All rights reserved.

PY - 2014/9/18

Y1 - 2014/9/18

N2 - We provide detailed mechanisms of Ahnak-mediated potentiation of transforming growth factor β (TGFβ) signaling, which leads to a negative regulation of cell growth. We show that Smad3 interacts with Ahnak through MH2 domain and that Ahnak stimulates Smad3 localization into nucleus leading to potentiating TGFβ-induced transcriptional activity of R-Smad. Moreover, overexpression of Ahnak resulted in growth retardation and cell cycle arrest through downregulation of c-Myc and cyclin D1/D2. We describe results from analyses of Ahnak-/-mouse model expressing middle T antigen in a mammary gland-specific manner (MMTV Tg/+ Ahnak-/-), which showed significantly progressed hyperplasia of mammary glands compared with MMTV Tg/+ Ahnak +/+. Finally, we screened multiple human breast cancer tissues and showed that the expression of Ahnak in cancer tissues is lower than that in control tissues by 50%. Taken together, these data indicate that Ahnak mediates a negative regulation of cell growth and acts as novel tumor suppressor through potentiation of TGFβ signaling.

AB - We provide detailed mechanisms of Ahnak-mediated potentiation of transforming growth factor β (TGFβ) signaling, which leads to a negative regulation of cell growth. We show that Smad3 interacts with Ahnak through MH2 domain and that Ahnak stimulates Smad3 localization into nucleus leading to potentiating TGFβ-induced transcriptional activity of R-Smad. Moreover, overexpression of Ahnak resulted in growth retardation and cell cycle arrest through downregulation of c-Myc and cyclin D1/D2. We describe results from analyses of Ahnak-/-mouse model expressing middle T antigen in a mammary gland-specific manner (MMTV Tg/+ Ahnak-/-), which showed significantly progressed hyperplasia of mammary glands compared with MMTV Tg/+ Ahnak +/+. Finally, we screened multiple human breast cancer tissues and showed that the expression of Ahnak in cancer tissues is lower than that in control tissues by 50%. Taken together, these data indicate that Ahnak mediates a negative regulation of cell growth and acts as novel tumor suppressor through potentiation of TGFβ signaling.

UR - http://www.scopus.com/inward/record.url?scp=84896421792&partnerID=8YFLogxK

U2 - 10.1038/onc.2014.69

DO - 10.1038/onc.2014.69

M3 - Article

C2 - 24662814

AN - SCOPUS:84896421792

SN - 0950-9232

VL - 33

SP - 4675

EP - 4684

JO - Oncogene

JF - Oncogene

IS - 38

ER -

Ahnak functions as a tumor suppressor via modulation of TGFβ/Smad signaling pathway

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this